NewAmsterdam Pharma Co. NV (NAMS)
27.40
+0.06
(+0.22%)
USD |
NASDAQ |
Aug 26, 16:00
27.40
0.00 (0.00%)
After-Hours: 17:03
NewAmsterdam Pharma Total Liabilities (Quarterly) : 73.03M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 73.03M |
| March 31, 2026 | 67.42M |
| December 31, 2025 | 85.85M |
| September 30, 2025 | 58.36M |
| June 30, 2025 | 36.62M |
| March 31, 2025 | 41.05M |
| December 31, 2024 | 107.12M |
| September 30, 2024 | 60.33M |
| June 30, 2024 | 59.25M |
| Date | Value |
|---|---|
| March 31, 2024 | 76.66M |
| September 30, 2022 | 12.21M |
| June 30, 2022 | 7.046M |
| March 31, 2022 | 6.034M |
| December 31, 2021 | 7.865M |
| September 30, 2021 | 8.270M |
| June 30, 2021 | 10.24M |
| March 31, 2021 | 9.364M |
| December 31, 2020 | 12.41M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| ProQR Therapeutics NV | 61.83M |
| Pharming Group NV | 210.95M |
| argenx SE | -- |
| Arcutis Biotherapeutics, Inc. | 267.96M |
| Damora Therapeutics, Inc. | 27.58M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 704.45M |
| Shareholders Equity (Quarterly) | 631.42M |
| Debt to Equity Ratio | 0.0001 |
| Current Ratio | 9.034 |
| Net Debt Paydown Yield | 0.00% |